Complement activation and inflammatory processes in drusen formation and age related macular degeneration

Experimental Eye Research

Volumn 73, Issue 6, 2001, Pages 887-896

  Johnson, Lincoln V ^a   Leitner, William P ^a   Staples, Michelle K ^a   Anderson, Don H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Complement; Drusen; Inflammation; Macular degeneration

Indexed keywords

CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; MEMBRANE COFACTOR PROTEIN; VITRONECTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOACCUMULATION; BRUCH MEMBRANE; CASE REPORT; CELL DEGENERATION; CELL ULTRASTRUCTURE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOPLASM; DRUSEN; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; RETINA MACULA AGE RELATED DEGENERATION; TISSUE DISTRIBUTION;

EID: 0035699547     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.2001.1094     Document Type: Article

References (58)

1. Drusen in age-related macular degeneration: Pathogenesis, natural course, and laser photocoagulation-induced regression
2. Immunocytochemical colocalization of clusterin in apoptotic photoreceptor cells in retinal degeneration slow rds mutant mouse retinas
3. Inflammation and Alzheimer's disease
4. Vitronectin gene expression in the adult human retina
5. Local cellular sources of drusen-associated molecules
6. Vitronectin receptor expression and distribution at the photoreceptor-retinal pigment epithelial interface
7. Expression and localization of apolipoprotein E in the neural retina and retinal pigmented epithelium: Implications for drusen formation and the pathogenesis of age-related macular degeneration
8. Bruch's membrane change with age
9. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration
10. Clinico-morphologic correlations of drusen of Bruch's membrane
11. Immunodeficiency of aging
12. Basal linear deposit and large drusen are specific for early age- related maculopathy
13. Age-related changes in the ultrastructure of Bruch's membrane
14. Complement components of the innate immune system in health and disease in the CNS
15. Drusen and disciform macular detachment and degeneration
16. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration
17. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells
18. Cell attachment on replicas of SDS polyacrylamide gels reveals two adhesive plasma proteins
19. Bruch's membrane and disease of the macula. Role of elastic tissue and collagen
20. Formation of drusen in the human eye
21. Age-related maculopathy: RPE, immune response molecules and drusen biogenesis
22. Evidence that drusen formation is a byproduct of complement-mediated attack on the retinal pigment epithelium
23. A potential role for immune complex pathogenesis in drusen formation
24. Inflammation and the immune response in age-related macular degeneration
25. Lack of causal relationship between clusterin expression and photoreceptor apoptosis in light-induced retinal degeneration
26. The immune complex pathogenesis of experimental membranous glomerulopathy (Heymann nephritis) and its significance in human glomerular disease
27. Age-related components of Bruch's membrane in the human eye
28. Genetic association of apolipoprotein E with age-related macular degeneration
29. Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster
30. Macular function impairment in eyes with early age-related macular degeneration
31. Macular drusen and the sensitivity of the central visual field
32. Effects of the membrane attack complex of complement on nucleated cells
33. Physiology and pathophysiology of complement: Progress and trends
34. Regulation of the complement membrane attack pathway
35. The complement system: An overview
36. Histochemical comparison of ocular drusen in monkey and human
37. Characterization of drusen-associated glycoconjugates
38. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease
39. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis
40. SP-40,40 is an inhibitor of C5b-6-initiated haemolysis
41. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays
42. The human retina and retinal pigment epithelium are abundant sources of vitronectin mRNA
43. Senile macular degeneration: The involvement of immunocompetent cells
44. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement
45. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration
46. Ageing and degeneration in the macular region: A clinico-pathological study
47. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: A clinicopathological study
48. Constitutive and regulated expression of vitronectin
49. Chronic low level complement activation within the eye is controlled intraocular complement regulatory proteins
50. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59
51. Immunologic privilege of the eye
52. Retinal sensitivity measurement over drusen using scanning laser ophthalmoscope microperimetry
53. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody
54. Scanning electron microscopy of human drusen
55. Early stages of age-related macular degeneration: An immunofluorescence and electron microscopy study
56. Structural and functional correlation of the human complement receptor type 1
57. Pathophysiology of age-related macular degeneration
58. Age-related macular degeneration: Review of pathogenesis